PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31444999-14	2019	Ponatinib treatment significantly increased plasma VEGF, soluble (s)VEGFR1, sVEGFR2, sTIE2, interferon gamma (IFNgamma), tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-6, IL-8, and IL-10 and decreased sVEGFR2.	ponatinib	0-9	interleukin 6	Homo sapiens	162-180	
30572654-3	2018	We found that Ponatinib inhibits STAT3 activity driven by EGF/EGFR, IL-6/IL-6R and IL-11/IL-11R, three major ligand/receptor systems involved in CRC development and progression.	ponatinib	14-23	interleukin 6	Homo sapiens	68-72